Clinical trial
Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of…
NCT00001693 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001693 |
|---|---|
| Title | Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers |
| Official title | Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasm, Hereditary Nonpolyposis |
| Intervention type | Drug |
| Interventions | Celecoxib (SC-58635) |
| Enrollment | 20 |
| Start date | Mar 1, 1998 |
| Completion | Jan 1, 2002 |
| First posted | Nov 4, 1999 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: